[go: up one dir, main page]

WO2012006865A1 - Utilisation de xanthoceras sorbifolia et d'extrait de xanthoceras sorbifolia dans la préparation de médicaments destinés au traitement de l'incontinence urinaire ou de la vessie hyperactive - Google Patents

Utilisation de xanthoceras sorbifolia et d'extrait de xanthoceras sorbifolia dans la préparation de médicaments destinés au traitement de l'incontinence urinaire ou de la vessie hyperactive Download PDF

Info

Publication number
WO2012006865A1
WO2012006865A1 PCT/CN2011/001077 CN2011001077W WO2012006865A1 WO 2012006865 A1 WO2012006865 A1 WO 2012006865A1 CN 2011001077 W CN2011001077 W CN 2011001077W WO 2012006865 A1 WO2012006865 A1 WO 2012006865A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
bladder
xanthoceras sorbifolia
urinary incontinence
contraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2011/001077
Other languages
English (en)
Chinese (zh)
Inventor
李滨生
刘沭军
杜涛
王晓良
张忠兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HARBIN THREE-HAPPINESS BIOENGINEERING Co Ltd
Original Assignee
HARBIN THREE-HAPPINESS BIOENGINEERING Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HARBIN THREE-HAPPINESS BIOENGINEERING Co Ltd filed Critical HARBIN THREE-HAPPINESS BIOENGINEERING Co Ltd
Publication of WO2012006865A1 publication Critical patent/WO2012006865A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Definitions

  • the present invention relates to a composition of a canopy and a plant extract thereof for preventing or treating the following urinary system diseases: urinary incontinence, enuresis, frequent urination and overactive bladder. Background technique
  • Overact ive Bladder is a syndrome characterized by urgency symptoms, often accompanied by frequent urination and nocturia symptoms, with or without urge incontinence; urodynamics can be expressed as Detrusor overactivity can also be other forms of urethral-bladder dysfunction.
  • Urinary incont inence is the involuntary loss of urine caused by impulsive (impulsive incontinence) or physical or mental stress (stress incontinence) caused by the inability of the bladder to retain urine.
  • the normal bladder fills up at physiological speed.
  • the bladder can accommodate large volumes of urine due to the physical properties of the bladder and the neurosuppression system. It is believed that the inhibition mechanism involves inhibition of parasympathetic activity or increased sympathetic tone resulting in detrusor relaxation and filling.
  • the bladder sphincter contracts during filling to prevent it from leaking.
  • the process of urination consists in relaxation of the bladder sphincter and subsequent contraction of the detrusor. When the bladder is empty, the urinary muscles relax and the sphincters contract to seal the bladder and maintain restraint.
  • Overactive bladder is an annoying and unwilling question, both men and women can develop symptoms.
  • treatment for urinary incontinence includes non-pharmacological treatments and medications.
  • Non-pharmacological treatment mainly involves self-training of the bladder. This method has a long course of treatment. The patient must have firm stamina and need to endure physical discomfort for a long time. Medication can quickly relieve symptoms and adjust the body and mind of the patient.
  • anticholinergic drugs are widely used in the treatment of overactive bladder and urge incontinence to relax the tension of bladder muscles.
  • the existing drugs of this type are less selective, There are a series of side effects such as dry mouth and constipation. Therefore, despite the effectiveness of existing therapies, there is still a large market demand for therapeutic drugs for UI and OAB.
  • Xanthoceras is a fruit of the genus Xanthoceras sorbifol ia Bunge, a perennial herb of the genus Corydalis. Xanthoceras is a perennial plant native to northern China and is now cultivated. Wenguan is mainly used for the treatment of rheumatoid arthritis, rheumatoid arthritis, and skin rheumatism. It was included in the Chinese Pharmacopoeia in 1977. The present inventors have found that the preparation containing the extract of Xanthocera or C. sinensis as the main component has an effective pharmacological action and an excellent therapeutic effect on UI and 0AB, and has no toxic side effects. Summary of the invention
  • the object of the present invention is to prove that the preparation of the extract of Xanthoceras sorbifolia and the extract of Xanthoceras sorbifolia is effective and less toxic for the treatment of urinary incontinence and overactive bladder for use in medicines and functional health foods.
  • the present invention antagonizes the effect of Ach (acetylcholine)-induced contraction of isolated bladder smooth muscle in rats by the effect of extract of Xanthoceras sorbifolia on isolated bladder smooth muscle of rats, and proves that the extract of Xanthoceras sorbifolia has a relaxing effect on bladder detrusor, possibly Antagonizing choline-like effects.
  • Ach acetylcholine
  • the effects of extracts of Xanthoceras sorbifolia L. on the in vitro bladder sphincter and the bioelectricity of extracellular electrodes of rabbit bladder external sphincter were demonstrated by the effect of extracts of Xanthoceras sorbifolia L. on the bladder sphincter.
  • the test animal strain used in the experimental examples of the present invention is a clean-grade Wi s tar rat.
  • the experimental method is to surgically extract the bladder and make a smooth muscle strip; the smooth muscle is placed in a constant temperature nutrient solution, and under the condition of oxygen supply, the crown is added.
  • Experimental Example 2 The extract of Xanthoceras sorbifolius antagonizes the effect of Ach contraction on isolated bladder smooth muscle of rats.
  • the experimental method was the same as Experimental Example 1.
  • EXPERIMENTAL EXAMPLE 3 Effect of extract of Acanthus chinensis, acetylcholine, and tolterodine tartrate on bladder and urethral sphincters in female non-fertility rats
  • the experimental animal strain used in the experimental examples of the present invention is a clean-grade Wi s tar rat.
  • the experimental method is to remove the bladder and urethra by surgery, remove the peripheral connective tissue, and take the material at the junction of the bladder and urethra to wake up and hang from the constant temperature nutrient solution.
  • the extract of Xanthoceras sorbifolia, acetylcholine, and tolterodine tartrate were added to observe the effects on the contraction rhythm and the amplitude of contraction.
  • Table 4A Effects of different concentrations of acetylcholine on contraction rhythm and contraction amplitude of bladder/urethral sphincter in female postpartum recovery
  • Experimental Example 5 Effect of extract of Xanthoceras sorbifolius on the bioelectricity of extracellular electrodes of rabbit bladder external sphincter
  • Experimental method The buried electrode was surgically placed, and the changes of extracorporeal sphincter in rabbits were recorded by physiological recorder.
  • Mode of administration Administration by intragastric administration.
  • Midodrine a drug called adrenaline, is a selective alpha.
  • Adrenergic receptor agonists commonly used in stress urinary incontinence.
  • Control group 30 5.5 ⁇ 3 ⁇ 0 4.2 ⁇ 1 ⁇ 8 0.2 ⁇ 0.1 m
  • Duo 10 0.4rag/kg 35.4 soil 11.6* ⁇ 14.9 ⁇ 6.7** 18.7 low soil dose 10 0. lg/kg 25.6 soil 10.1* * 9.7 ⁇ 4.2** 8.2 high soil dose 10 0.2g/kg 31.3 ⁇ 12.8*' * 13.9 ⁇ 5.4** 12.6 soil
  • the test animal strain used in the experimental examples of the present invention was a clean-grade Kunming mouse, and was administered orally.
  • the extract of Xanthoceras sorbifolia was derived from Refining Example 4, and was made into a capsule.
  • the control drug Imipramine has a strong antidepressant effect and a weak atropine-like effect, and is often used in depression and enuresis in children.
  • the experimental method is based on the color reaction of potassium iodide and starch drying in urine, and the number of urination is calculated.
  • Experimental Example 7 Effect of extract of Xanthoceras sorbifolia L. on leakage point pressure after pudendal nerve injury in rats
  • Experimental method Wi s tar rats were anesthetized with 10% hydrated chlorinated phenol, fixed on the operating table, and disinfected in double groin The posterior opening is separated from the tibia to the sciatic nerve fossa along the abdominal wall, and the vaginal nerve under the occlusion of the bilateral sciatic nerve is cut off and sutured. Sham-operated animals were only isolated to the sciatic nerve fossa. Animals were dosed 18 days after surgery, and administered 1 hour before the test on 21 days, and the bladder leak point pressure was measured.
  • Wis tar rats were intravesically implanted with PE- 50 catheter for bladder pressure measurement at 7, 10, and 14 days, and the bladder volume and maximum pressure during urination were observed.
  • Twenty bladder pressure measuring solutions were citric acid, and 10 rats in the control group were physiological saline; 20 rats were intraperitoneally implanted with PE- 50 catheter and then infused with the extract of C. elegans.
  • Bladder pressure was measured before perfusion, 2 days and 6 days after perfusion.
  • Ten pressure-measuring solutions were citric acid and 10 were normal saline.
  • Group average bladder pressure measurement volume (ml) Xanthoceras sorbifolia extract perfusion of the extract of the extract of the corolla fruit, 2 days after the infusion of the extract of the corolla fruit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne l'utilisation de xanthoceras sorbifolia et d'extrait de xanthoceras sorbifolia dans la préparation de médicaments destinés au traitement de l'incontinence urinaire ou de la vessie hyperactive. L'invention porte en outre sur une composition médicale destinée au traitement de l'incontinence urinaire ou de la vessie hyperactive, qui contient 1 à 99 % de xanthoceras sorbifolia ou d'extrait de xanthoceras sorbifolia.
PCT/CN2011/001077 2010-07-16 2011-06-30 Utilisation de xanthoceras sorbifolia et d'extrait de xanthoceras sorbifolia dans la préparation de médicaments destinés au traitement de l'incontinence urinaire ou de la vessie hyperactive Ceased WO2012006865A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201010228470.5 2010-07-16
CN201010228470 2010-07-16

Publications (1)

Publication Number Publication Date
WO2012006865A1 true WO2012006865A1 (fr) 2012-01-19

Family

ID=45468905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001077 Ceased WO2012006865A1 (fr) 2010-07-16 2011-06-30 Utilisation de xanthoceras sorbifolia et d'extrait de xanthoceras sorbifolia dans la préparation de médicaments destinés au traitement de l'incontinence urinaire ou de la vessie hyperactive

Country Status (1)

Country Link
WO (1) WO2012006865A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104147376A (zh) * 2014-09-01 2014-11-19 郑峰 一种治疗脑卒中后尿失禁的中药组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1052636C (zh) * 1993-03-29 2000-05-24 中国科学院沈阳应用生态研究所 文冠果子的醇提取物在制备治疗智力低下的药物中的应用
US20050276872A1 (en) * 2001-08-31 2005-12-15 Chan Pui-Kwong Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
CN100346805C (zh) * 2001-10-31 2007-11-07 杨柏珍 治疗脑功能低下、抗糖尿病活性的文冠果果壳提取物
CN102151305A (zh) * 2010-02-10 2011-08-17 哈尔滨三乐生物工程有限公司 文冠果提取物、其提取方法及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1052636C (zh) * 1993-03-29 2000-05-24 中国科学院沈阳应用生态研究所 文冠果子的醇提取物在制备治疗智力低下的药物中的应用
US20050276872A1 (en) * 2001-08-31 2005-12-15 Chan Pui-Kwong Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
CN100346805C (zh) * 2001-10-31 2007-11-07 杨柏珍 治疗脑功能低下、抗糖尿病活性的文冠果果壳提取物
CN102151305A (zh) * 2010-02-10 2011-08-17 哈尔滨三乐生物工程有限公司 文冠果提取物、其提取方法及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104147376A (zh) * 2014-09-01 2014-11-19 郑峰 一种治疗脑卒中后尿失禁的中药组合物

Similar Documents

Publication Publication Date Title
CN107126490A (zh) 一种防治胃肠功能障碍的中药组合物及其制备方法
CN104606456A (zh) 一种治疗高血压、高血脂的保健药物
WO2012006865A1 (fr) Utilisation de xanthoceras sorbifolia et d'extrait de xanthoceras sorbifolia dans la préparation de médicaments destinés au traitement de l'incontinence urinaire ou de la vessie hyperactive
CN101933963A (zh) 一种治疗头痛的鼻用原位凝胶剂
CN110141619B (zh) 一种治疗便秘的中草药组合物及其凝胶贴剂的制备方法
CN103585585A (zh) 一种治疗胆总管结石的中药组合物及其制备方法
CN103330815B (zh) 一种治疗性功能障碍的中药喷剂
JP7157253B2 (ja) 潤腸便通の漢方薬組成物、その調製方法及びその用途
CN107753921A (zh) 一种治疗妊娠剧吐的中药贴脐剂
CN102614375B (zh) 一种补肾壮阳、治疗阳痿的中药组合物及其制备方法
CN101444614B (zh) 具有燃脂紧肤作用的药物组合物及其制备方法
CN111643580B (zh) 一种用于治疗视神经脊髓炎的中药组合物
CN110051778A (zh) 一种用于治疗慢性咽炎的利咽茶及其制备方法
CN108096484A (zh) 一种用于主动脉夹层围手术期的中药组合物及应用
CN100444855C (zh) 一种内服用于治疗腹泻的药粉
CN103784881B (zh) 一种治疗痛经的中药组合物及其制备方法
CN119770595A (zh) 一种治疗肾气不固型遗尿病的中药组合物
CN102772585B (zh) 一种治疗阑尾炎的药物组合物及其制备方法和用途
CN100540036C (zh) 玉米叶提取物用于抗抑郁及改善性功能的应用
CN103933202A (zh) 一种消肿止痛的中草药及其制备方法
CN115844943A (zh) 大豆黄卷在治疗膀胱过度活动症中的应用
CN103932168B (zh) 一种治疗功能性便秘的保健汤及其制备方法
CN103251770A (zh) 一种治疗羊胎衣不下的组合物及其制备方法
CN102836343B (zh) 一种用于结肠护理和治疗结肠炎的药物
CN112933178A (zh) 一种治疗冠心病心律不齐的中药组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11806207

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11806207

Country of ref document: EP

Kind code of ref document: A1